Jefferies Financial Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Jefferies Financial Group’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-29,909	Closed	-$3.95M	–	1912
2025 Q1	$3.95M	Buy	+29,909	New	+$3.73M	0.03%	365
2024 Q3	–	Sell	-17,000	Closed	-$1.16M	–	1828
2024 Q2	$1.16M	Buy	+17,000	New	+$1.18M	0.01%	696
2024 Q1	–	Sell	-29,000	Closed	-$2.08M	–	2115
2023 Q4	$2.08M	Buy	29,000 +28,840	+18,025%	+$1.66M	0.01%	698
2023 Q3	$8.33K	Buy	+160	New	+$9.32K	﹤0.01%	1548

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Jefferies Financial Group's ITCI Position: Q2 2025 in Review

Jefferies Financial Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 29,909 shares — an estimated $3.95M sold.

Jefferies Financial Group first reported a position in ITCI in Q3 2023 and held it in 4 quarters. The position peaked at $3.95M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Jefferies Financial Group reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Jefferies Financial Group sold 29,909 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $3.95M.
Jefferies Financial Group first reported a position in Intra-Cellular Therapies Inc. in Q3 2023 and held it in 4 quarters.
Jefferies Financial Group's Intra-Cellular Therapies Inc. position peaked at $3.95M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Jefferies Financial Group's 13F filing for Q2 2025, filed 12 Aug 2025.